Fig. 3: Summary of the results of the systematic reviews and meta-analyses investigating the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on liver outcomes in chronic hepatitis B (CHB).
From: Diagnosing and defining MASLD in people living with chronic hepatitis B
-- No impact on outcome, ↑ outcome increased in people living with CHB and MASLD compared to CHB alone, ↓ outcome decreased in people living with CHB and MASLD compared to CHB alone. The first author of the meta-analysis and the year published are stated. A list of these meta-analyses is presented linked to full citations in Table 1.
